Literature DB >> 10363968

Recombinant virus vaccination against "self" antigens using anchor-fixed immunogens.

K R Irvine1, M R Parkhurst, E P Shulman, J P Tupesis, M Custer, C E Touloukian, P F Robbins, A G Yafal, P Greenhalgh, R P Sutmuller, R Offringa, S A Rosenberg, N P Restifo.   

Abstract

To study the induction of anti-"self" CD8+ T-cell reactivity against the tumor antigen gp100, we used a mouse transgenic for a chimeric HLA-A*0201/H-2 Kb molecule (A2/Kb). We immunized the mice with a recombinant vaccinia virus encoding a form of gp100 that had been modified at position 210 (from a threonine to a methionine) to increase epitope binding to the restricting class I molecule. Immunogens containing the "anchor-fixed" modification elicited anti-self CD8+ T cells specific for the wild-type gp100(209-217) peptide pulsed onto target cells. More important, these cells specifically recognized the naturally presented epitope on the surface of an A2/Kb-expressing murine melanoma, B16. These data indicate that anchor-fixing epitopes could enhance the function of recombinant virus-based immunogens.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10363968      PMCID： PMC2249691     

Source DB:  PubMed          Journal:  Cancer Res        ISSN： 0008-5472            Impact factor:   12.701


  23 in total

1.  Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma.

Authors:  S A Rosenberg; J C Yang; D J Schwartzentruber; P Hwu; F M Marincola; S L Topalian; N P Restifo; M E Dudley; S L Schwarz; P J Spiess; J R Wunderlich; M R Parkhurst; Y Kawakami; C A Seipp; J H Einhorn; D E White
Journal:  Nat Med       Date:  1998-03       Impact factor: 53.440

Review 2.  Probing degeneracy in T-cell recognition using peptide combinatorial libraries.

Authors:  B Hemmer; M Vergelli; C Pinilla; R Houghten; R Martin
Journal:  Immunol Today       Date:  1998-04

Review 3.  Tumor vaccines--a reality at last?

Authors:  I Hellström; K E Hellström
Journal:  J Immunother       Date:  1998-03       Impact factor: 4.456

4.  MHC class I-associated peptides produced from endogenous gene products with vastly different efficiencies.

Authors:  L C Anton; J W Yewdell; J R Bennink
Journal:  J Immunol       Date:  1997-03-15       Impact factor: 5.422

5.  MHC affinity, peptide liberation, T cell repertoire, and immunodominance all contribute to the paucity of MHC class I-restricted peptides recognized by antiviral CTL.

Authors:  Y Deng; J W Yewdell; L C Eisenlohr; J R Bennink
Journal:  J Immunol       Date:  1997-02-15       Impact factor: 5.422

Review 6.  Danger versus tolerance: paradigms for future studies of tumor-specific cytotoxic T lymphocytes.

Authors:  R G Fenton; D L Longo
Journal:  J Natl Cancer Inst       Date:  1997-02-19       Impact factor: 13.506

7.  Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100.

Authors:  Y Zhai; J C Yang; P Spiess; M I Nishimura; W W Overwijk; B Roberts; N P Restifo; S A Rosenberg
Journal:  J Immunother       Date:  1997-01       Impact factor: 4.456

Review 8.  Immunotherapy of melanoma.

Authors:  M S Mitchell
Journal:  J Investig Dermatol Symp Proc       Date:  1996-04

9.  Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors.

Authors:  K R Irvine; R S Chamberlain; E P Shulman; D R Surman; S A Rosenberg; N P Restifo
Journal:  J Natl Cancer Inst       Date:  1997-11-05       Impact factor: 13.506

10.  gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand.

Authors:  W W Overwijk; A Tsung; K R Irvine; M R Parkhurst; T J Goletz; K Tsung; M W Carroll; C Liu; B Moss; S A Rosenberg; N P Restifo
Journal:  J Exp Med       Date:  1998-07-20       Impact factor: 14.307
View more
  11 in total

1.  Mining the melanosome for tumor vaccine targets: P.polypeptide is a novel tumor-associated antigen.

Authors:  C E Touloukian; W W Leitner; P F Robbins; S A Rosenberg; N P Restifo
Journal:  Cancer Res       Date:  2001-11-15       Impact factor: 12.701

2.  Mouse model for pre-clinical study of human cancer immunotherapy.

Authors:  Zhiya Ya; Yared Hailemichael; Willem Overwijk; Nicholas P Restifo
Journal:  Curr Protoc Immunol       Date:  2015-02-02

3.  Increased immunogenicity of an anchor-modified tumor-associated antigen is due to the enhanced stability of the peptide/MHC complex: implications for vaccine design.

Authors:  Oleg Y Borbulevych; Tiffany K Baxter; Zhiya Yu; Nicholas P Restifo; Brian M Baker
Journal:  J Immunol       Date:  2005-04-15       Impact factor: 5.422

4.  T-cell receptor affinity and avidity defines antitumor response and autoimmunity in T-cell immunotherapy.

Authors:  Shi Zhong; Karolina Malecek; Laura A Johnson; Zhiya Yu; Eleazar Vega-Saenz de Miera; Farbod Darvishian; Katelyn McGary; Kevin Huang; Josh Boyer; Emily Corse; Yongzhao Shao; Steven A Rosenberg; Nicholas P Restifo; Iman Osman; Michelle Krogsgaard
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-01       Impact factor: 11.205

Review 5.  Adoptive immunotherapy for cancer: harnessing the T cell response.

Authors:  Nicholas P Restifo; Mark E Dudley; Steven A Rosenberg
Journal:  Nat Rev Immunol       Date:  2012-03-22       Impact factor: 53.106

6.  Both CD4 and CD8 T cells mediate equally effective in vivo tumor treatment when engineered with a highly avid TCR targeting tyrosinase.

Authors:  Timothy L Frankel; William R Burns; Peter D Peng; Zhiya Yu; Dhanalakshmi Chinnasamy; Jennifer A Wargo; Zhili Zheng; Nicholas P Restifo; Steven A Rosenberg; Richard A Morgan
Journal:  J Immunol       Date:  2010-04-28       Impact factor: 5.422

Review 7.  Building better vaccines: how apoptotic cell death can induce inflammation and activate innate and adaptive immunity.

Authors:  N P Restifo
Journal:  Curr Opin Immunol       Date:  2000-10       Impact factor: 7.486

Review 8.  Cancer vaccines: translation from mice to human clinical trials.

Authors:  Hoyoung Maeng; Masaki Terabe; Jay A Berzofsky
Journal:  Curr Opin Immunol       Date:  2018-03-16       Impact factor: 7.486

Review 9.  Dendritic cells based immunotherapy.

Authors:  Na Shang; Matteo Figini; Junjie Shangguan; Bin Wang; Chong Sun; Liang Pan; Quanhong Ma; Zhuoli Zhang
Journal:  Am J Cancer Res       Date:  2017-10-01       Impact factor: 6.166

10.  Poor immunogenicity of a self/tumor antigen derives from peptide-MHC-I instability and is independent of tolerance.

Authors:  Zhiya Yu; Marc R Theoret; Christopher E Touloukian; Deborah R Surman; Scott C Garman; Lionel Feigenbaum; Tiffany K Baxter; Brian M Baker; Nicholas P Restifo
Journal:  J Clin Invest       Date:  2004-08       Impact factor: 14.808
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.